Todo S, Fung J J, Tzakis A, Demetris A J, Jain A, Alessiani M, Takaya S, Day R, Gordon R, Starzl T E
Department of Surgery, University of Pittsburgh, PA.
Transplant Proc. 1991 Feb;23(1 Pt 2):1397-402.
An account is given of the 6- to 12-month survival, and causes of failure in 110 consecutive patients who underwent primary liver transplantation under treatment from the outset with FK 506 and steroids. The patient survival is 92.7%, and the first graft survival is 87.3%. At a very high frequency, the patients achieved good graft function, and they had a relatively low morbidity that was partially ascribable to minimal use and early discontinuance (in 60% of cases) of steroids. Renal dysfunction and other adverse findings were largely confined to patients with poor initial graft function and consequent apparent alteration of the kinetics of FK 506 elimination, causing functional overdosage. Results compare very favorably with our past record using conventional immunosuppression, and support the belief that FK 506 is a superior immunosuppressive agent which is suitable for chronic administration.
本文报道了110例从一开始就接受FK506和类固醇治疗的初次肝移植患者6至12个月的生存率及失败原因。患者生存率为92.7%，首次移植肝生存率为87.3%。患者移植肝功能良好的频率很高，发病率相对较低，部分原因是类固醇用量极少且早期停药（60%的病例）。肾功能不全和其他不良表现主要局限于初始移植肝功能差且随后FK506消除动力学明显改变导致功能性过量的患者。结果与我们过去使用传统免疫抑制的记录相比非常有利，并支持FK506是一种适合长期给药的 superior免疫抑制剂的观点。
